Maia Biotechnology Insider Bought Shares Worth $299,409, According to a Recent SEC Filing
Stan Smith, Director, on April 25, 2024, executed a purchase for 147,492 shares in Maia Biotechnology (MAIA) for $299,409. Following the Form 4 filing with the SEC, Smith has control over a total of 1
MT NewswiresApr 26 17:37 ET
Express News | MAIA Biotechnology Announces $1M Private Placement Of 494,096 Shares At $2.034/Share
Moomoo 24/7Apr 23 08:52 ET
Express News | Maia Biotechnology Announces $1.00 Million Private Placement
Moomoo 24/7Apr 23 08:51 ET
NYSE American Net Change Percentage Gainers & Losers
GAINERS COMPANY SYMBOL LAST CHANGE PERCENT VOLUME ------- ------ ---- ------ ------- ------ CPI Aerost
Dow JonesApr 8 17:45 ET
MAIA Biotechnology to Present at Two Investor Conferences in April 2024
MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that Chairman and Chief Executive Officer Vlad
BusinesswireApr 5 08:01 ET
MAIA Biotechnology Boosts CEO Jeffrey Himmelreich's Salary
TipRanksApr 2 16:22 ET
MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero
Company recognizes significant support by board members in recent private placement MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted
BusinesswireMar 28 15:00 ET
MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement
Five independent members of MAIA's Board of Directors purchased shares in the offering MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted
BusinesswireMar 26 15:00 ET
MAIA Biotechnology Announces $1.33 Million Private Placement
MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements
BusinesswireMar 26 08:01 ET
Express News | Maia Biotechnology Increased Maximum Aggregate Offering Price Of Shares Of Common Stock, Issuable Under At Market Offering Agreement
Moomoo 24/7Mar 25 16:11 ET
CGC, CYTO and IDN Are Among Mid-day Movers
Seeking AlphaMar 25 13:25 ET
MAIA Biotechnology at Risk of NYSE Delisting Over Equity Shortfalls
TipRanksMar 23 02:02 ET
MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement
Dr. Smith has participated in every MAIA funding round MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA," the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today
BusinesswireMar 22 15:00 ET
MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to Its Scientific Advisory Board
Acclaimed academic researcher has led 40+ multicenter phase 2 and phase 3 clinical studies MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing
BusinesswireMar 21 15:00 ET
Director Ngar Louie Acquires 170,940 Shares of MAIA Biotechnology Inc (MAIA)
Yahoo FinanceMar 16 01:49 ET
Maia Biotechnology Director Buys $8.1k in Company Shares
InvestingMar 15 19:06 ET
MAIA Biotechnology up 3%, Raises $2.9MM via Private Placement
Seeking AlphaMar 14 02:39 ET
Express News | MAIA Biotechnology Shares Halted On Code News Pending
Moomoo 24/7Mar 13 13:33 ET
MAIA Biotechnology to Participate in the 36th Annual ROTH Conference
MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced its participation in the 36th Annual ROTH
BusinesswireMar 7 09:45 ET
PWM, RVSN and AISP Among Pre-market Losers
Seeking AlphaMar 7 08:35 ET
No Data
No Data